Cogentus Pharmaceuticals - Top 20 VC deals of 2007

Company: Cogentus Pharmaceuticals
Based: Menlo Park, CA
Amount: $55M
Round: Third
Investors: Pinnacle Ventures, Prospect Venture Partners, Undisclosed Investor

Scoop: Cogentus' lead therapy is CGT-2168, a once-daily oral formulation that combines clopidogrel with a gastroprotectant that is designed to significantly reduce the gastrointestinal side effects commonly associated with antiplatelet therapy. Two Phase III clinical trials of CGT-2168 are underway.

Cogentus Pharmaceuticals - Top 20 VC deals of 2007

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i